NasdaqGS:NUVLBiotechs
Is Nuvalent’s ASCO ALKOVE-1 and ARROS-1 Data Altering The Investment Case For Nuvalent (NUVL)?
Nuvalent recently presented pivotal ALKOVE-1 data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC and preliminary ARROS-1 data for zidesamtinib in ROS1-positive solid tumors other than NSCLC at the 2026 ASCO Annual Meeting, supporting its recent FDA NDA submission and ongoing Phase 3 ALKAZAR trial.
An interesting angle is how zidesamtinib’s early results in ROS1-positive tumors beyond lung cancer highlight Nuvalent’s effort to broaden targeted therapy applications.
We’ll now...